Company intelligence / Profile preview

Matrizyme Pharma

Ownership: Private
Development stage: Phase 3

Overview

Matrizyme Pharma develops an innovative collagenase-based injectable therapy designed to facilitate angioplasty in patients with chronic total occlusions, aiming to reduce the need for invasive surgeries. Their lead program targets coronary occlusion and appears to be in a pending or early-stage clinical phase. No published late-stage results are available as of May 2025[2][4][5].

Therapeutic areas: Cardiovascular
Modalities: Enzyme therapy (collagenase injection)
Industry: Biotech

Drug pipeline

1 asset

MZ-004

Beyond the preview

Go deeper on Matrizyme Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Matrizyme Pharma.

Explore the full profile